Studies by Mujahid and co-workers have demonstrated that mutations in the BBS1 gene are associated with the most severe clinical manifestations of metabolic dysfunction in BBS patients, including obesity, insulin resistance, and dyslipidemia [7]. This evidence concerns the gene BBS1 and Bardet-Biedl syndrome.